Literature DB >> 26755227

Socioeconomic inequities and payment coping mechanisms used in the treatment of type 2 diabetes mellitus in Nigeria.

I L Okoronkwo1, J N Ekpemiro, O E Onwujekwe, A C Nwaneri, P N Iheanacho.   

Abstract

AIM: Given the enormous economic burden of diabetes in Nigeria and in sub-Saharan Africa, the study was designed to determine how different population groups cope with payment for type 2 diabetes mellitus (DM).
MATERIALS AND METHODS: A total of 292 exit interviews were conducted with patients who attended the outpatient diabetic clinic in a specialist public health facility in southeast Nigeria. The monthly expenditures and strategies that were used to cope with payments for diabetic treatment were determined. A socioeconomic status (SES) index was used to divide the respondents into SES quartiles (Q1 (poorest), Q2, Q3, Q4 (least poor)). The coping mechanisms were disaggregated by SES.
RESULTS: The mean monthly expenditure for the treatment of diabetes was ₦56,245.11 ($356). Expenditures were mostly incurred through out-of-pocket payments. The most common coping strategy utilized was household savings (99.0%) followed by support from family members (85.3%). All SES groups used more than one payment coping method. Borrowing, skipping of appointments, and stopping children education were significantly significant (P < 0.05).
CONCLUSION: The mean monthly direct cost in the treatment of type 2 diabetes among the study group was high. There were SES inequities in the use of coping mechanisms, with the poorest SES group (Q1) being worse off than other groups. The financial risk protection mechanisms such as health insurance that will reduce the economic burden of type 2 diabetes on households and provide universal health coverage to people suffering from DM more especially to the disadvantaged group should be developed and implemented.

Entities:  

Mesh:

Year:  2016        PMID: 26755227     DOI: 10.4103/1119-3077.173711

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  6 in total

1.  Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia.

Authors:  Mengistu Bekele; Ole Frithjof Norheim; Alemayehu Hailu
Journal:  MDM Policy Pract       Date:  2021-04-27

2.  Scaling-up strategic purchasing: analysis of health system governance imperatives for strategic purchasing in a free maternal and child healthcare programme in Enugu State, Nigeria.

Authors:  Daniel Chukwuemeka Ogbuabor; Obinna Emmanuel Onwujekwe
Journal:  BMC Health Serv Res       Date:  2018-04-05       Impact factor: 2.655

Review 3.  Readiness of Sub-Saharan Africa Healthcare Systems for the New Pandemic, Diabetes: A Systematic Review.

Authors:  Bernardo Nuche-Berenguer; Linda E Kupfer
Journal:  J Diabetes Res       Date:  2018-02-18       Impact factor: 4.011

4.  Catastrophic health expenditure and impoverishment for type 2 diabetes mellitus patients in a multiethnic province in China using a Blinder-Oaxaca decomposition: A cross-sectional study.

Authors:  Xian Sun; Tippawan Liabsuetrakul; Xiaomin Xie; Ping Liu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 5.  The household financial burden of non-communicable diseases in low- and middle-income countries: a systematic review.

Authors:  Joseph Kazibwe; Phuong Bich Tran; Kristi Sidney Annerstedt
Journal:  Health Res Policy Syst       Date:  2021-06-21

Review 6.  Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future.

Authors:  Brian Godman; Debashis Basu; Yogan Pillay; Julius C Mwita; Godfrey Mutashambara Rwegerera; Bene D Anand Paramadhas; Celda Tiroyakgosi; Patrick Mbah Okwen; Loveline Lum Niba; Justice Nonvignon; Israel Sefah; Margaret Oluka; Anastasia N Guantai; Dan Kibuule; Francis Kalemeera; Mwangana Mubita; Joseph Fadare; Olayinka O Ogunleye; Larry A Distiller; Enos M Rampamba; Jeffrey Wing; Debjani Mueller; Abubakr Alfadl; Adefolarin A Amu; Zinhle Matsebula; Aubrey Kalungia; Trust Zaranyika; Nyasha Masuka; Janney Wale; Ruaraidh Hill; Amanj Kurdi; Angela Timoney; Stephen Campbell; Johanna C Meyer
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.